Biotech Values

[biomaven0]

>FGEN IP

Worth noting that Neff mentioned a new patent filing related to Cmin. Whether that might hold up or not I have no idea.

This isn't a great candidate for a biosimilar - the inherently high COGS will cut into margins, not to mention the start-up costs for a huge plant.

FGEN has also been burnt before on both kidney and liver fibrosis - the endpoints are hard, although you could now piggyback off the other NASH players. Those early FGEN trials were almost certainly significantly under-dosed as well.

For example, this was run at 5 and 10mg/kg:

https://clinicaltrials.gov/ct2/show/NCT00754143?term=fg-3019&draw=1&rank=6